Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
•
tnbc
How do you administer chemotherapy with Y90 for a triple negative breast cancer patient with BRCA1+ and liver only metastases who is not a candidate for repeat SBRT?
Related Questions
Would you consider a PARP inhibitor in metastatic TNBC with high LOH on NGS?
Since the publication of DESTINY-Breast-04 have you implemented new institutional practices for characterization of HER2-low disease given known limitations in pathologist IHC evaluation?
In which scenarios do you stage breast cancer using CT and nuclear bone scans versus PET-CT?
How should we think about endocrine resistance in patients with inherited germline mutations such as BRCA, CHEK2, etc.?
What strategies do you implement to control the nausea from Enhertu?
What are your top takeaways in Breast Cancer from ASCO 2023?
Do you consider post-NAC isolated tumor cells in LNs to be residual disease in TNBC to justify capecitabine?
How do you approach treatment in a young de novo metastatic HER2+ HR(-) breast cancer patient with extensive intraparenchymal and leptomeningeal carcinomatosis?
Do you routinely check echocardiograms on all patients who are starting TDM1?
Would you consider using tucatinib in a patient with de-novo metastatic HER2+ HR(-) breast cancer patient with extensive intraparenchymal and leptomeningeal carcinomatosis?